Neurotech Demonstrates Potential Benefits for Management of Multiple Sclerosis Disease
Finfeed
Archived
May 25, 2021
Initial in vitro studies carried out by Neurotech International Limited (ASX: NTI) in collaboration with the internationally recognised Neurodevelopment in Health and Disease Laboratory at RMIT University to assess the effects of the lead NTI/Dolce strains on key neuro-markets that are used in assessing the onset and progression of Multiple Sclerosis (MS).
